Sharp continued rise. They have announced that the results of the Phase 1 clinical trial for their self-produced CAR-T cell therapy (NIB102), which targets solid tumors, were reported at the Annual Meeting of the American Society of Clinical Oncology. They found that there were no observed dose-limiting toxicities, and suggested that there was efficacy, with anti-tumor effects observed in liver cancer patients and tumors shrinking. In the future, after receiving the rights to develop and commercialize from Takeda Pharmaceutical Co., Ltd. <4502>, Noile-Immune Biotech will take the lead in development.
ノイルイミューン---大幅に続伸、固形がん対象の自家CAR-T細胞療法の臨床試験結果を米学会で報告
Noileumune - significant increase, reported clinical trial results of CAR-T cell therapy for solid tumors at a US congress.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.